• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

CLDN4 Expression Causally Increases Ovarian Cancer Risk in Multi-Omics Study

by
November 13, 2026
in Cancer, Health
Reading Time: 3 mins read
0
CLDN4 Expression Causally Increases Ovarian Cancer Risk in Multi-Omics Study

CLDN4 Expression Causally Increases Ovarian Cancer Risk in Multi-Omics Study

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An integrative multi-omics investigation has established a positive causal relationship between CLDN4 expression and ovarian cancer risk, identifying the gene as a candidate therapeutic target and diagnostic biomarker. The finding, supported by summary Mendelian randomization analysis at a significance threshold of P < 0.05, highlights CLDN4 among a broader set of genomic markers tied to disease risk and tumor immunology.

Ovarian cancer remains a highly lethal malignancy constrained by limited diagnostic biomarkers and therapeutic targets. In response to these clinical limitations, the research team designed a multi-phase computational and genetic workflow aimed at uncovering robust diagnostic signatures, characterizing immune infiltration patterns, and distinguishing causal disease drivers from non-causal associations.

To prioritize candidate genes across large-scale biological cohorts, the investigators integrated multiple public transcriptomic datasets from the Gene Expression Omnibus, The Cancer Genome Atlas, and the Genotype-Tissue Expression project. The team then applied differential gene expression analysis alongside weighted gene co-expression network analysis to isolate key co-expression modules and candidate genes from the combined expression data.

Candidate signatures were subsequently evaluated through an extensive machine learning pipeline incorporating 113 distinct models. When validated across independent patient cohorts, an eight-gene diagnostic signature composed of KDR, CLDN4, CAV1, BMP2, CLDN7, SNCA, FGF13, and AGTR1 demonstrated high diagnostic performance for identifying ovarian cancer cases.

Using the CIBERSORT algorithm to quantify immune cell composition within the tumor microenvironment, the researchers assessed how signature genes correlated with immune cell subsets. Among the evaluated targets, CAV1, FGF13, and KDR displayed positive correlations with M2 macrophage infiltration, suggesting potential mechanistic roles in immune evasion.

To establish causality beyond correlative expression patterns, the study performed summary Mendelian randomization by integrating blood expression quantitative trait loci data with genome-wide association study data from FinnGen. This genetic causal inference, combined with transcriptomic profiling and functional validation, established a positive causal link between CLDN4 expression and ovarian cancer risk, offering a verified foundation for translational oncology research.

Beyond the primary causal identification, the investigative framework relies on a multi-tiered validation structure designed to connect computational gene prioritization with actionable biological insight. The research strategy pairs transcriptomic associations derived from public expression repositories with genetic causal inference and experimental functional validation, creating a linked progression from computational discovery to laboratory confirmation in ovarian cancer pathology.

By grounding gene identification in independent cohorts and functional assays, the study addresses common obstacles in ovarian oncology, where limited diagnostic biomarkers and therapeutic targets have historically impeded clinical management. The integration of high-dimensional expression datasets with targeted causal modeling demonstrates how computational modeling pipelines, comprising 113 distinct model architectures, can isolate specific diagnostic candidates from complex genomic landscapes.

The study authors emphasize that these combined findings provide fresh perspectives on the molecular mechanisms governing ovarian cancer pathogenesis. Identifying CLDN4 as both an essential biomarker candidate and a prospective therapeutic target establishes an empirical baseline for future translational research, offering concrete molecular targets for subsequent experimental and clinical oncology investigations.

Subject of Research: Identification of CLDN4 as a causal gene and therapeutic target in ovarian cancer

Article Title: Multi-omics and functional validation identify CLDN4 as a therapeutic target in ovarian cancer

Article References: Ling, Q., Chen, Y., Wu, L., Xu, H., Zhang, Z., Chen, J., Lai, H., Yao, S., Zhao, R., Yang, G., & He, W. (2026). Multi-omics and functional validation identify CLDN4 as a therapeutic target in ovarian cancer. Discover Oncology. https://doi.org/10.1007/s12672-026-06291-4

Image Credits: AI Generated

DOI: 10.1007/s12672-026-06291-4

Keywords: ovarian cancer, CLDN4, summary Mendelian randomization, transcriptomics, machine learning, CIBERSORT, M2 macrophages, immune evasion, KDR, CAV1, FGF13, BMP2, CLDN7, SNCA, AGTR1, WGCNA, eQTL, FinnGen GWAS

News Source: Nathaniel Bowman. (November 13, 2026). CLDN4 Expression Causally Increases Ovarian Cancer Risk in Multi-Omics Study. Scienmag.

Tags: AGTR1BMP2CAV1CIBERSORTCLDN4CLDN7eQTLFGF13FinnGen GWASimmune evasionKDRM2 macrophagesMachine LearningOvarian cancerSNCAsummary Mendelian randomizationTranscriptomicsWGCNA
Share12Tweet7Share2ShareShareShare1

Related Posts

SENEX Expression Promotes Apoptosis Resistance and Invasive Growth in Burkitt Lymphoma

SENEX Expression Promotes Apoptosis Resistance and Invasive Growth in Burkitt Lymphoma

November 16, 2026
Maternal Poor Sleep Quality Linked to Congenital Heart Defects in Offspring

Maternal Poor Sleep Quality Linked to Congenital Heart Defects in Offspring

November 16, 2026

Simulation Tool for Omentectomy Demonstrates Reliability but Lacks Trainee Discrimination

November 16, 2026

Personalized Neoantigen Vaccines Show Promise in Treating Gastrointestinal Cancers

November 16, 2026

POPULAR NEWS

  • Chaotic Encryption Scheme Secures Sensitive Image Regions Using Blurring and Scrambling

    Chaotic Encryption Scheme Secures Sensitive Image Regions Using Blurring and Scrambling

    29 shares
    Share 12 Tweet 7
  • Problematic Smartphone Use Linked to Youth Distress in Comparative Study

    29 shares
    Share 12 Tweet 7
  • Dynamo Protocol Models Single-Cell Vector Fields to Predict Lineage Fate Transitions

    29 shares
    Share 12 Tweet 7
  • Global Meta-Analysis Reveals 5.5 Percent Nontuberculous Mycobacteria Prevalence in HIV Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

SENEX Expression Promotes Apoptosis Resistance and Invasive Growth in Burkitt Lymphoma

FWB-SMOTE Algorithm Outperforms Eleven Benchmarks on Imbalanced Datasets Across Three Classifiers

Smoothing Methods Enhance Machine Learning State-of-Health Predictions for Lithium-Ion Batteries

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.